The Xpert GI Panel identifies pathogens directly from stool specimens collected in Cary-Blair transport media.

Renowned molecular diagnostics provider Cepheid CPHD recently entered into a non-exclusive distribution agreement with Henry Schein Medical, the Medical business of one of the leading healthcare ...

Cepheid announced today that it has received FDA clearance for Xpert GI Panel, a multiplex PCR test designed to provide fast ...

Cepheid's performance in the first quarter was driven by robust growth in clinical product sales resulting from test utilization in the emerging HAI test market for Xpert MRSA, continued adoption of ...

SUNNYVALE, Calif., Oct. 28, 2025 /PRNewswire/ -- Cepheid today announced that its Xpert® MTB/XDR test has been awarded prequalification status by the World Health Organization (WHO), marking a new ...

Sherlock Biosciences has teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech for new tests on the latter’s automated laboratory systems. The collaboration will focus on ...

SUNNYVALE, Calif. (AP) -- Molecular diagnostics company Cepheid said Thursday it took a loss in the third quarter on costs related to a patent lawsuit. In late September Cepheid agreed to settle a ...

Cepheid (NAS: CPHD) carries $32.2 million of goodwill and other intangibles on its balance sheet. Sometimes goodwill, especially when it's excessive, can foreshadow problems down the road. Could this ...

Cepheid 's ( CPHD) sales under the HBDC (high burden developing countries) program are likely to get a boost from a $30 million funding approval from UNITAID. The approved fund would go a long way to ...

Shares jump on the news that the company is being bought out by Danaher. Danaher has offered to by Cepheid for $4 billion in cash, valuing shares at $53 each. That represents a premium of 54% based on ...

A new diagnostic test for the novel coronavirus will return results in just 45 minutes, four times faster than existing machines. But the test, emergency use of which was cleared by the Food and Drug ...

Shareholders ofCepheid(NASDAQ: CPHD), a molecular diagnostics company,are having a pleasant start to the short trading week. News broke this morning that the company has agreed to be acquired by ...